Details

Autor(en) / Beteiligte

• Garabet, Lamya Samir Noori
• Eriksson, Anna Maria
• Tjønnfjord, Eirik
• Cui, Xueyan
• Olsen, Magnus Kringstad
• Jacobsen, Hege
• Jørgensen, Camilla Tøvik
• Mathisen, Åse-Berit
• Mowinckel, Marie-Christine
• Ahlen, Maria Therese
• Sørvoll, Ingvild Hausberg
• Horvei, Kjersti Daae
• Ernstsen, Siw Leiknes
• Lægreid, Ingvild Jenssen
• Stavik, Benedicte
• Holst, Rene
• Sandset, Per Morten
• Ghanima, Waleed

Titel

SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people

Ist Teil von

• Research and practice in thrombosis and haemostasis, 2023

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Background SARS-CoV-2 adenoviral vector DNA vaccines have been linked to the rare but serious thrombotic postvaccine complication vaccine-induced immune thrombotic thrombocytopenia. This has raised concerns regarding the possibility of increased thrombotic risk after any SARS-CoV-2 vaccines. Objectives To investigate whether SARS-CoV-2 vaccines cause coagulation activation leading to a hypercoagulable state. Methods This observational study included 567 health care personnel; 521 were recruited after the first dose of adenoviral vector ChAdOx1-S (Vaxzevria, AstraZeneca) vaccine and 46 were recruited prospectively before vaccination with a messenger RNA (mRNA) vaccine, either Spikevax (Moderna, n = 38) or Comirnaty (Pfizer-BioNTech, n = 8). In the mRNA group, samples were acquired before and 1 to 2 weeks after vaccination. In addition to the prevaccination samples, 56 unvaccinated blood donors were recruited as controls (total n = 102). Thrombin generation, D-dimer levels, and free tissue factor pathway inhibitor (TFPI) levels were analyzed. Results No participant experienced thrombosis, vaccine-induced immune thrombotic thrombocytopenia, or thrombocytopenia (platelet count <100 × 109/L) 1 week to 1 month postvaccination. There was no increase in thrombin generation, D-dimer level, or TFPI level in the ChAdOx1-S vaccine group compared with controls or after the mRNA vaccines compared with baseline values. Eleven of 513 (2.1%) participants vaccinated with ChAdOx1-S had anti-PF4/polyanion antibodies without a concomitant increase in thrombin generation. Conclusion In this study, SARS-CoV-2 vaccines were not associated with thrombosis, thrombocytopenia, increased thrombin generation, D-dimer levels, or TFPI levels compared with baseline or unvaccinated controls. These findings argue against the subclinical activation of coagulation post-COVID-19 vaccination.